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Abstract
Latently-infected CD4+ T cells are widely considered to be the major barrier to a cure for
HIV. Much of our understanding of HIV latency comes from latency models and blood cells,
but most HIV-infected cells reside in lymphoid tissues such as the gut. We hypothesized
that tissue-specific environments may impact the mechanisms that govern HIV expression.
To assess the degree to which different mechanisms inhibit HIV transcription in the gut and
blood, we quantified HIV transcripts suggestive of transcriptional interference (U3-U5;
"Read-through"), initiation (TAR), 5’ elongation (R-U5-pre-Gag; "Long LTR"), distal tran-
scription (Nef), completion (U3-polyA; "PolyA"), and multiple splicing (Tat-Rev) in matched
peripheral blood mononuclear cells (PBMCs) and rectal biopsies, and matched FACS-
sorted CD4+ T cells from blood and rectum, from two cohorts of ART-suppressed individu-
als. Like the PBMCs, rectal biopsies showed low levels of read-through transcripts (median
= 23 copies/106 cells) and a gradient of total (679)>elongated(75)>Nef(16)>polyadenylated
(11)>multiply-spliced HIV RNAs(<1) [p<0.05 for all], demonstrating blocks to HIV transcrip-
tional elongation, completion, and splicing. Rectal CD4+ T cells showed a similar gradient of
total>polyadenylated>multiply-spliced transcripts, but the ratio of total to elongated tran-
scripts was 6-fold lower than in blood CD4+ T cells (P = 0.016), suggesting less of a block to
HIV transcriptional elongation in rectal CD4+ T cells. Levels of total transcripts per provirus
were significantly lower in rectal biopsies compared to PBMCs (median 3.5 vs. 15.4; P =
0.008) and in sorted CD4+ T cells from rectum compared to blood (median 2.7 vs. 31.8; P =
0.016). The lower levels of HIV transcriptional initiation and of most HIV transcripts per pro-
virus in the rectum suggest that this site may be enriched for latently-infected cells, cells in
which latency is maintained by different mechanisms, or cells in a "deeper" state of latency.
These are important considerations for designing therapies that aim to disrupt HIV latency in
all tissue compartments.







Citation: Telwatte S, Lee S, Somsouk M, Hatano H,
Baker C, Kaiser P, et al. (2018) Gut and blood differ
in constitutive blocks to HIV transcription,
suggesting tissue-specific differences in the
mechanisms that govern HIV latency. PLoS Pathog
14(11): e1007357. https://doi.org/10.1371/journal.
ppat.1007357
Editor: Bryan R. Cullen, Duke University Medical
Center, UNITED STATES
Received: June 8, 2018
Accepted: September 27, 2018
Published: November 15, 2018
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced,
distributed, transmitted, modified, built upon, or
otherwise used by anyone for any lawful purpose.
The work is made available under the Creative
Commons CC0 public domain dedication.
Data Availability Statement: All relevant data are
within the paper and/or Supporting Information
files.
Funding: This work was supported by the U.S.
Department of Veterans Affairs [IK2 CX000520
(SAY) and I01 BX000192 (JKW)], the National
Institute of Diabetes and Digestive and Kidney
Diseases at the NIH [1R01DK108349 (SAY)], the
National Institute of Allergy and Infectious Diseases
at the NIH [1R01AI132128 (SAY and JKW),
Author summary
Available antiretroviral drugs significantly prolong life expectancy and reduce morbidity
in people living with HIV. However, HIV can escape host immune responses and drug
treatment by establishing a reversibly silent ("latent") infection in CD4+ T cells. This latent
infection represents the major barrier to a cure. While much of the research to date has
highlighted the importance of peripheral CD4+ T cells as reservoirs for latent HIV, it is
becoming increasingly apparent that the gut may play an integral role as a major tissue
reservoir for HIV. In this study, we show that the transcriptional blocks that underlie HIV
latency in CD4+ T cells differ in the blood and gut. In HIV-infected people on effective
treatment, the major blocks to HIV transcription in blood cells occur at transcriptional
elongation, distal transcription/polyadenylation (completion), and splicing. In the gut, the
major block to HIV transcription occurs at transcriptional initiation, suggesting that HIV
latency is maintained by different mechanisms in the gut, which may be enriched for
latently-infected cells and/or cells in a "deeper" state of latency. These differences in the
blocks to HIV transcription are important to consider in designing therapies that aim to
cure HIV.
Introduction
The major barrier to a cure for HIV is thought to be latently-infected cells that do not produce
HIV constitutively but can be induced to produce infectious virus upon activation [1–3]. The
latent HIV reservoir cannot be eliminated using currently available antiretroviral drugs, and
due to their long half-lives and ability to proliferate [4], latently-infected cells can persist for
many years [5–8]. While an extensive body of research has underscored the importance of
peripheral CD4+ T cells as reservoirs for latent HIV, it is becoming increasingly apparent that
the gut may play an integral role as a major tissue reservoir for HIV [9]. First, a large propor-
tion of all lymphocytes reside in lymphoid tissue, of which the gut accounts for up to 85 per
cent [10]. Second, CD4+ T cells of the gut are likely to be more vulnerable to infection than
their peripheral blood counterparts [10]. This increased permissivity to HIV [11, 12] may be
due to factors such as elevated levels of activation or CCR5 expression [13–15]. Consequently,
the depletion of CD4+ T cells in the gut during acute HIV [16] and SIV [17–21] infection is
both more rapid and severe than peripheral blood. Furthermore, this depletion occurs prior to
and is more profound than that in the blood or lymph nodes [17, 22]. The disproportionate
effect of HIV infection on the gut may result in an increased HIV burden in gastrointestinal
tissue. Both HIV DNA and RNA are found to be concentrated in the gut [23, 24] and replica-
tion-competent HIV has been recovered from the rectal mucosa [25], suggesting that a propor-
tion of gut CD4+ T cells harbor replication-competent proviruses. Prior data also suggest
differences between blood and gut in infected cell types, levels of T cell activation, HIV DNA
levels, relationship to activation, and levels of HIV RNA per cell [23, 26], suggesting these tis-
sues differ in the mechanisms that govern HIV transcription and latency.
Using a novel panel of reverse transcription droplet digital polymerase chain reaction (RT-
ddPCR) assays that can simultaneously quantify multiple different blocks to HIV transcrip-
tion, we recently showed that the major reversible blocks to HIV transcription in peripheral
CD4+ T cells from ART-suppressed patients are blocks to proximal elongation, distal tran-
scription/polyadenylation (completion), and splicing [27]. We hypothesized that the mecha-
nisms and degrees of HIV transcriptional blocks underlying HIV latency differ between gut
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and peripheral blood. In this study, we applied our "transcriptional profiling" assays to two
cohorts of ART-suppressed individuals to simultaneously assess the mechanisms that govern
HIV transcription in the gut and blood. We quantified the levels of different HIV RNAs in
PBMCs and intact rectal biopsies (n = 9), as well as sorted CD4+ T cells from peripheral blood
and dissociated rectal biopsies (n = 7). The relative levels of the different HIV RNAs suggested
blocks to distal HIV transcription, completion, and splicing in all samples, and these observa-
tions were not explained by mutations in the corresponding HIV DNA primer/probe sequences
or differential RNA stabilities. However, in contrast to our findings in peripheral CD4+ T cells
[27], we found a much greater block to HIV transcriptional initiation in the rectum (both biop-
sies and sorted cells) compared to the blood. These differences in HIV transcriptional blocks,
which could reflect tissue-specific differences in viral or cellular factors, are important to con-
sider in designing therapies that aim to eliminate or silence HIV-infected cells.
Results
HIV transcription profile suggests successive blocks to HIV transcriptional
elongation, completion, and splicing in PBMCs and rectal biopsies
We used a novel panel of HIV “transcription profiling” assays (Fig 1) to quantify HIV tran-
scripts suggestive of transcriptional interference (U3-U5; "Read-through"), initiation (TAR
[Trans-activation Response region]), 5’ elongation (R-U5-pre-Gag; "Long LTR” [Long Termi-
nal Repeat]), distal transcription (Nef), completion (U3-polyA; "PolyA"), and multiple splicing
(Tat-Rev) in PBMCs and intact rectal biopsies from nine ART-suppressed individuals. In
PBMCs, these assays revealed a reproducible gradient in the relative abundance of HIV tran-
scripts (normalized to cell equivalents by ddPCR for Telomere Reverse Transcriptase [TERT])
where total (TAR) > elongated (Long LTR) > distally elongated (Nef) > polyadenylated
(PolyA) > multiply-spliced Tat-Rev transcripts (medians: 7289, 420, 108, 44, and 2 copies/106
Fig 1. The HIV genome and the targets for transcription profiling assays. This schematic shows the genetic organization of proviral HIV DNA and the HIV
‘transcription profiling’ assays targeting specific RNA sequence regions that provide insight into blocks to transcription. Some proposed mechanisms underlying
the blocks to transcription initiation, elongation, and splicing are detailed.
https://doi.org/10.1371/journal.ppat.1007357.g001
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cells, respectively; Fig 2A). Read-through transcripts (U3-U5), suggestive of transcriptional
interference, were also detected in every individual (median 155 copies/106 cells), but were
30-fold lower than total (TAR) transcripts (median [Read-through/TAR ratio] = 0.033). The
median level of 5’ elongated (Long-LTR) transcripts was 17-fold lower than that of total tran-
scripts (median [Long LTR/TAR] = 0.06), suggesting a block to proximal elongation. The
median level of Nef (3’) was almost 4-fold lower than that of 5’ elongated transcripts (median
[Nef/Long LTR] = 0.26), suggesting a block to distal transcription. The median level of multi-
ply-spliced transcripts was 23-fold lower than levels of polyadenylated transcripts (median
[MS Tat-Rev/PolyA] = 0.04), in accord with prior data suggesting a reversible block to multiple
splicing [27].
A similar trend in relative transcript levels (albeit at lower overall levels) was observed in
the rectal biopsies, wherein the relative abundance of HIV transcripts was also: total>
Fig 2. HIV RNA levels and HIV RNA/DNA ratios reveal blocks to elongation, distal transcription, and multiple-splicing in PBMCs and intact gut biopsies.
Read-through, total (TAR), 5’ elongated (R-U5/pre-Gag; “Long LTR”), Nef, polyadenylated (PolyA), and multiply-spliced Tat-Rev (MS Tat-Rev) HIV RNAs were
measured in (A) PBMCs; and (B) intact rectal biopsies (n = 9 ART-suppressed individuals). 2C-D: Levels of HIV transcription per provirus are lower in the gut
than the blood. Levels of each HIV RNA were normalized to HIV DNA from the same sample as measured by (C) ddPCR for the corresponding DNA sequence
region (PolyA was normalized to the Read-through assay, which employs the same forward primer/probe), except for MS Tat-Rev where there is no DNA
equivalent; or (D) ddPCR for the Long LTR assay, which is present once in each intact provirus. Bars indicate the median. Comparisons between transcripts were
performed using the Wilcoxon signed-rank test.
https://doi.org/10.1371/journal.ppat.1007357.g002
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elongated > Nef> polyadenylated > multiply-spliced Tat-Rev (medians: 679, 75, 16, 11, and
<1 copies/106 cells, respectively; Fig 2B). Just as in the PBMCs, Read-through transcripts were
detected in all individuals (median 23 copies/106 cells), but were much lower than that of total
transcripts (47-fold lower; median [Read-through/TAR] = 0.021). The median level of elon-
gated transcripts was 9-fold lower than that of total transcripts (median [Long LTR/TAR] =
0.11). The median level of distally-elongated (Nef) transcripts was 4-fold lower than that of 5’
elongated transcripts (median [Nef/Long LTR] = 0.21), and the level of polyadenylated tran-
scripts was nearly 2-fold lower than that of distally-elongated transcripts (median [PolyA/Nef]
= 0.66]). A block to multiple-splicing is also likely (PolyA > MS Tat-Rev), given that polyade-
nylated HIV transcripts were detected in rectal biopsies from 6 of 9 individuals, while MS Tat-
Rev transcripts were detected in biopsies from only 2 of 9 individuals (vs. 5 of 9 from PBMCs;
Fig 2A and 2B). These data suggest that in both PBMCs and rectal biopsies, HIV transcription
is blocked at the stages of elongation, distal transcription/polyadenylation (completion), and
splicing.
Differences in HIV RNA levels are unlikely to be driven by proviral
deletions or hypermutations in primer/probe regions
To address the possibility that proviral deletions or hypermutations in primer/probe regions
could account for the varying levels of HIV transcripts, we quantified the levels of U3-U5
("Read-through"), TAR, Long LTR and Nef in DNA extracted in parallel with the RNA from
the same PBMCs and rectal biopsies (n = 9 individuals) using the same primers/probes and
ddPCR conditions used to measure each HIV RNA (S1 Fig). Comparisons between DNA
from the same tissue revealed no differences in the levels of TAR and Read-through regions
(both present at 2 copies in an intact provirus) and these levels were�2-fold greater than long
LTR DNA (1 copy per intact provirus) in rectal biopsies and PBMCs (median TAR/Long
LTR = 1.99 and 3.49, respectively; S1 Fig). Levels of Nef DNA (1 copy per intact provirus) were
similar to Long LTR DNA and tended to be lower than both Read-through and TAR DNA for
both tissues (P<0.05 for all comparisons).
Next, we measured the ratio of each HIV RNA to the corresponding HIV DNA sequence
region quantified using the same ddPCR assay (Fig 2C) and normalized to 106 cells in the
same manner. This measure expresses the average level of transcription per provirus and is
independent of normalization to cell numbers. For both PBMCs and intact biopsies, the gradi-
ent pattern in the levels of successive HIV transcripts was preserved after normalization of
each HIV RNA region to the corresponding HIV DNA region, suggesting that the differences
are unlikely to be due to proviral deletions or hypermutations in primer/probe regions.
Lower transcription per provirus of most HIV RNAs in intact rectal
biopsies compared to PBMCs
The average level per provirus of each HIV transcript was quantified using two approaches.
First, we expressed the ratio of each HIV transcript to HIV DNA measured using the same
primers/probe (Fig 2C), which revealed lower levels of Read-through, TAR and Nef transcripts
per provirus in intact rectal biopsies compared to PBMCs (P<0.05 for all). As an orthogonal
method, we expressed the ratio of each HIV transcript to DNA measured using the Long LTR
assay alone, which is present in only one copy per intact provirus. This analysis revealed the
same trend for all transcripts (Fig 2D; P<0.05 for all). Together, these data strongly suggest
lower levels of HIV transcriptional initiation and distal transcription, in addition to lower lev-
els of transcriptional interference, in the rectal biopsies relative to PBMCs.
Transcriptional blocks underlying HIV latency differ in the gut and blood
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Differences in ex vivo HIV transcript stability do not drive the differences
in levels
To determine whether sequence-specific differences in RNA stability/degradation contribute to
the divergent levels of HIV transcripts detected, we measured the RNA decay rate of each tran-
script in peripheral CD4+ T cells isolated from an ART-suppressed patient in the presence or
absence of the RNA Pol II inhibitors Triptolide (Fig 3A) or Actinomycin D (Fig 3B). In the
absence of RNA Pol II inhibitors, levels of each HIV transcript over 16 hours (h) remained rela-
tively stable (S2 Fig). In contrast, the presence of either Triptolide (100nM) or Actinomycin D (5
mg/mL) resulted in decay of all HIV transcripts over 16h, irrespective of normalization (Fig 3, S1
Table). The half-lives of TAR- and Long LTR-containing transcripts were similar (in the order of
~3–5 hours) irrespective of treatment (Triptolide or Actinomycin D) and generally similar to the
half-lives of read-through, Nef, and PolyA transcripts in the presence of Triptolide (4.58, 2.80 and
2.29h, respectively), although the latter three transcripts had shorter half lives in the presence of
Actinomycin D (2.54, 1.66, and 2.34h, respectively). The half-life of MS Tat-Rev transcripts was
longer with Triptolide (6.25h) and Actinomycin D (5.49h) treatments. The relatively short, similar
half-lives of most HIV transcripts (S1 Table) suggest rapid decay in vivo, and any differences do
not readily account for the measured differences in levels of the various HIV RNAs.
HIV DNA and 2-LTR circles trend higher in rectal CD4+ T cells than blood
CD4+ T cells
Since PBMCs and gut biopsies contain different mixtures of T and non-T cells, we also com-
pared CD4+ T cells (defined as CD3+CD8-) sorted from blood and dissociated rectal biopsies
from a different cohort of seven ART-suppressed patients. HIV DNA (as measured by the
Long LTR assay) was higher in CD4+ T cells from the rectum (10,736 copies/106 CD4+ T
cells) than blood (3,841 copies/106 CD4+ T cells; P = 0.016; Fig 4A). HIV DNA can exist in
non-integrated or episomal forms, such as 2-LTR circles, which have been interpreted as either
labile markers of recent infection or stable forms that decrease only with cell division [28, 29].
Therefore, we also measured the levels of 2-LTR circles using a new assay (S3 Fig), as well as
Fig 3. Stability of HIV transcripts ex vivo. Peripheral CD4+ T cells were isolated from an ART-suppressed individual and treated with the RNA polymerase II (RNA
Pol II) inhibitors (A) Triptolide [100 nM] or (B) Actinomycin D [5 mg/mL] to arrest de novo cellular and viral transcription. HIV transcripts (Read-through, TAR,
Long LTR, Nef, PolyA, and MS Tat-Rev) were quantified using RT-ddPCR from cells harvested at various time points post-treatment. Levels of each HIV RNA were
expressed as a proportion of the level at time t = 0 (shown) and the half-lives were determined using a one-phase exponential decay model. Data normalized to DNA
mass are shown.
https://doi.org/10.1371/journal.ppat.1007357.g003
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the levels of 2-LTR circles relative to total HIV DNA, in the blood and rectal CD4+ T cells by
ddPCR. 2-LTR circles were detected in both blood and rectal CD4+ T cells from the same 5 of
7 individuals, and in 4 of these individuals, levels of 2-LTR circles/106 CD4+ T cells (normal-
ized by TERT) were higher in the rectum (Fig 4A). However, the ratio of 2-LTR HIV DNA to
total HIV DNA did not appear to differ in CD4+ T cells from rectum and blood.
Greater block to HIV transcription initiation in CD4+ T cells from rectum
compared to blood
In order to measure blocks to HIV transcription in the sorted CD4+ T cells, levels of read-
through, total, elongated, completed, and multiply-spliced Tat-Rev transcripts were measured
by RT-ddPCR (S4 Fig). Since HIV DNA levels differed in the CD4+ T cells from blood and
Fig 4. Levels of HIV DNA, 2-LTR circles, and blocks to transcription differ between CD4+ T cells from the gut and blood. (A) Levels of HIV DNA (Long LTR
region) and 2-LTR circles were quantified in CD4+ T cells from the blood and rectum using ddPCR and expressed as copies per million CD4+ T cells (normalized
by TERT). (B) The average levels per provirus of each transcript (ratio of each HIV RNA to the Long LTR HIV DNA) were measured in CD4+ T cells isolated from
the blood and rectum (n = 7 matched individuals). (C) The ratio of TAR to Long LTR RNA was determined to compare the block to transcriptional elongation in
CD4+ T cells from the blood and rectum. (D) The ratio of Read-through to Long LTR RNA was determined to assess the contribution of transcriptional
interference to the block to HIV transcription initiation in rectal CD4+ T cells relative to peripheral CD4+ T cells. Bars represent medians. Comparisons between
transcripts were performed using the Wilcoxon signed-rank test.
https://doi.org/10.1371/journal.ppat.1007357.g004
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rectum, levels of each HIV RNA were divided by the HIV DNA (measured using the Long
LTR assay) to express the average transcription per provirus (Fig 4B). In CD4+ T cells from
both sites, we observed low average levels per provirus of read-though transcripts compared to
total transcripts, suggesting little transcriptional interference, and a gradient where elongated
> polyadenylated >multiply-spliced transcripts, suggesting blocks to distal transcription and
splicing. For the four individuals for whom ileal CD4+ T cells were available, we observed a
similar trend (S5 Fig). As in the rectal biopsies, levels of total (TAR) transcripts per provirus
were much lower (median 12-fold) in rectal CD4+ T cells compared to peripheral CD4+ T
cells (Fig 4B; P = 0.016), suggesting less initiation of HIV transcription in the rectum. Unlike
the intact rectal biopsies, PBMCs, or blood CD4+ T cells, we observed no difference between
levels of elongated (Long LTR) and total (TAR) transcripts in the rectal CD4+ T cells (Fig 4B).
With the caveat that isolation of gut CD4+ T cells requires additional processing, these data
suggest little or no block to elongation in the sorted rectal CD4+ T cells.
Block to transcriptional elongation is greater in CD4+ T cells from blood
compared to rectum
Ratios of one HIV transcript to another are independent of normalization to cell numbers and
can be used to measure the presence and degree of different HIV transcriptional blocks [27].
We did not find a difference between PBMCs and rectal biopsies in the proportion of HIV tran-
scripts that are read-through (read-through/total) or in the proportion of HIV transcripts that
proceed through blocks to elongation (elongated/total), completion (polyadenylated/elongated),
or multiple splicing (MS Tat-Rev/polyadenylated). In contrast, the sorted CD4+ T cells from
blood and rectum showed a 6-fold difference in the proportion of HIV transcripts blocked at
the stage of elongation (P = 0.016; Fig 4C), with little block to elongation in the rectal CD4+ T
cells (median total/elongated = 1.31) and a strong block to elongation in CD4+ T cells from the
blood (median total/elongated = 7.50). These data suggest that a block to HIV transcriptional
initiation plays a greater role in inhibiting virus expression in the rectal CD4+ T cells, whereas a
block to elongation likely plays a bigger role in CD4+ T cells from the blood.
Lower transcription initiation in the gut is unlikely to be driven by
transcriptional interference
Blocks to HIV transcriptional initiation could be due to transcriptional interference caused by
transcription from neighboring cellular genes that perturbs assembly of preinitiation com-
plexes at the 5’ HIV LTR [30]. To assess the likely contribution of transcriptional interference
to the decreased HIV transcriptional initiation in rectal CD4+ T cells, we measured levels of
read-through transcripts in relation to total and elongated HIV transcripts. A trend toward
lower read-through/elongated transcripts was observed in sorted CD4+ T cells from rectum
compared to blood (0.03 vs. 0.08, respectively, P = 0.078; Fig 4D), suggesting less transcrip-
tional interference in the rectal CD4+ T cells. Furthermore, the levels of read-through tran-
scripts tended to be low compared to total transcripts in all samples from both tissues. These
findings suggest that transcriptional interference plays a relatively modest role in inhibiting
HIV transcription in both sites.
Collagenase treatment does not degrade HIV RNA or change the pattern of
differences between HIV transcripts
It is conceivable that the process of dissociating gut tissue using collagenase may degrade HIV
RNA, which could contribute to lower levels of HIV RNAs in the sorted gut CD4+ T cells but
Transcriptional blocks underlying HIV latency differ in the gut and blood
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007357 November 15, 2018 8 / 28
not the intact biopsies. Alternatively, the tissue processing could induce HIV transcriptional
elongation, which could contribute to the lower block to elongation in sorted gut CD4+ T
cells. To address these concerns, we treated PBMCs from an HIV-infected individual using the
same protocol employed for dissociation of gut biopsies. HIV RNA transcripts were measured
in PBMCs that were untreated, FACS-stained only, or collagenase treated and FACS-stained
(S6 Fig). Interestingly, we found that the FACS-staining procedure necessary to sort live cells
of interest may itself cause increases in HIV transcription. In PBMCs that were not treated
with collagenase but were FACS-stained, an increase was observed in all HIV transcripts in
relation to untreated PBMCs (S6 Fig). FACS-staining alone resulted in a 6.6- and 4.4-fold
increase in MS Tat-Rev relative to untreated cells when normalized by RNA mass and TERT,
respectively. In contrast, the combination of collagenase treatment and FACS-staining resulted
only in an ~2.5 fold increase in MS Tat-Rev relative to untreated cells. The effect of collagenase
without FACS staining was also determined in PBMCs from a second HIV-infected individual
(S6 Fig). Collagenase treatment alone increased levels of all HIV RNA transcripts, although the
change was less than two-fold for each transcript irrespective of normalization (S6 Fig). Colla-
genase treatment did not alter the pattern of differences between various HIV transcripts.
Given that the flash-frozen biopsies that were not subject to collagenase treatment also demon-
strated lower levels of HIV transcription, these data support our findings that RNA stability or
processing disparities do not account for differences in HIV transcription between tissues.
Discussion
The reversible lack of virus expression in latently-infected cells is widely considered to be the
main barrier to cure of HIV, but it is unclear what mechanisms inhibit constitutive virus
expression in lymphoid tissues such as the gut, where most infected cells reside, or whether
these mechanisms differ from HIV-infected cells in the blood. In this study, we employed our
"transcriptional profiling" [27, 31] approach to measure the degree to which different mecha-
nisms inhibit HIV transcription (and hence virus expression) in gut and blood within HIV
+ individuals on suppressive ART.
We measured levels of six HIV transcripts in blood and rectum from two different cohorts
of ART-suppressed patients. Distinct types of samples were chosen to minimize sample pro-
cessing that could affect transcription (PBMCs and flash frozen biopsies) or to facilitate com-
parison between the same cell type (sorted CD4+ T cells from blood and rectum). In both
blood samples and the rectal biopsies, we observed a reproducible pattern in the abundance of
HIV transcripts that declined in successive increments (TAR>Long LTR> Nef> PolyA > MS
Tat-Rev). These findings, which accord with our previous findings in peripheral CD4+ T cells
from ART-suppressed individuals [27], suggest constitutive blocks to HIV transcriptional
elongation (TAR > long LTR), distal HIV transcription (Long LTR> Nef), completion (Long
LTR> PolyA), and multiple splicing (PolyA > MS Tat-Rev). In contrast to these results from
the blood and even the biopsies, we found little evidence for a block to elongation in the rectal
CD4+ T cells. Moreover, the average levels of total (TAR) transcripts per provirus were much
lower in both types of rectal samples than the corresponding blood samples, suggesting a
much greater block to HIV transcriptional initiation in the rectum.
Validations
As with any study that attempts to quantify levels of RNA or DNA, differing assay efficiencies
can greatly influence the levels of RNA or DNA detected and thus interpretations of these
data. Our transcription profiling approach utilizes special methods to minimize bias towards
any one sequence region, and we have previously measured the performance characteristics of
Transcriptional blocks underlying HIV latency differ in the gut and blood
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each assay [27, 31]. Given that all our HIV assays demonstrate similar efficiencies [27], it is
unlikely that differing assay characteristics account for the marked differences between levels
of the various HIV RNAs.
Internal deletions and hypermutations are present in a substantial proportion of proviral
sequences [32, 33] and could cause sequence mismatches with primers or probes, which could
impair detection of some HIV transcripts [33]. To assess the impact of proviral sequence, we
measured the levels of each sequence region (except Tat-Rev) in the DNA from the PBMCs
and rectal biopsies, and we also normalized levels of each RNA to levels of the corresponding
DNA measured using the same assays employed for the HIV RNA and normalized to 106 cells
using the same method (Fig 2C). The gradient in levels of different HIV RNAs was preserved
even after normalizing to the corresponding DNA, and was similar when all RNAs were nor-
malized to the same Long LTR DNA region (Fig 2D), underscoring that these differences in
RNA levels cannot be attributed solely to mutations in the corresponding DNA sequence
regions. We were unable to quantify HIV DNA regions other than the Long LTR region in the
sorted CD4+ T cells, for which the detection of 2-LTR circles consumed a large proportion of
the DNA, but it seems unlikely that these would differ much from the results in PBMCs and
gut biopsies.
RNA stability
The steady state level of each HIV RNA likely reflects a balance between production (transcrip-
tion) and destruction (degradation). To determine whether sequence-specific differences in
RNA stability could contribute to differences in levels of the HIV RNAs, we measured the
decay of Read-through, TAR, Long LTR, Nef, PolyA, and MS Tat-Rev transcripts in CD4+ T
cells from an ART-suppressed individual using two RNA Pol II inhibitors, Triptolide and Acti-
nomycin D. In Triptolide-treated cells, the half-lives of Nef (2.80h), PolyA (2.29h), and Read-
through (4.58h) did not vary considerably from TAR and Long LTR (3.13h and 2.86h, respec-
tively). MS Tat-Rev seemed to be more stable than the other HIV transcripts after treatment
with Triptolide (6.25h) and Actinomycin D (5.49h). However, the very low levels of MS Tat-
Rev cause considerable imprecision in calculating its half-life, and even if MS Tat-Rev tran-
scripts were more stable, this would not explain the very low levels of MS Tat-Rev relative to
other HIV RNAs.
The half-lives determined from decay of HIV transcripts in cells treated with Triptolide
tended to be higher than those determined from cells treated with Actinomycin D. Triptolide
acts by inducing proteasome-dependent degradation of RNA Pol II [34], whereas Actinomycin
D is thought to intercalate into DNA to sterically-inhibit RNA Pol II [35]. Potential discrepan-
cies in the half lives measured with Triptolide and Actinomycin could be due to the different
mechanisms by which these agents inhibit RNA Pol II, incomplete arrest of de novo transcrip-
tion, or imprecision due to the limited number of time points. For both Actinomycin and
Triptolide, the most striking observation is that the half-lives of less abundant HIV transcripts,
such as Read-through, Nef, PolyA, and MS Tat-Rev, are comparable to those transcripts that
are detected at much higher levels (TAR and Long LTR). These data strongly argue that differ-
ences in RNA stability alone do not explain the differential abundance of these HIV tran-
scripts. Although we did not have sufficient numbers of rectal CD4+ T cells to assess the
stability of these transcripts in the rectum, and cellular factors may contribute to differences
between cell or tissue types, it seems unlikely that there are major sequence-dependent differ-
ences between the various HIV transcripts.
Surprisingly, these data also demonstrate that the half-lives of all HIV transcripts tested
were relatively short (<7 hours for all except MS Tat-Rev). The short half-life of the TAR
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transcripts and the average levels of TAR RNA per provirus (>2) suggest a dynamic transcrip-
tional environment with multiple rounds of HIV transcription initiation per day per provirus
in the PBMCs, in contrast to the prevailing model of transcriptionally-silent proviruses in ART-
suppressed individuals. Ultimately, however, HIV transcripts may be maintained at low levels,
despite their active transcription, because of rapid RNA turnover rates, particularly in activated
T cells [36]. Furthermore, blocks to elongation and splicing could lead to low expression of HIV
Rev, which is critical in circumventing the degradation of unspliced viral transcripts containing
introns and AU-rich sequences that contribute to instability [37, 38]. The presence of instability
elements within gag also contribute to HIV-1 unspliced mRNA instability [39]. The expression
of Gag, Pol, Vif, Vpr, Vpu, and Env proteins from unspliced and partially spliced human immu-
nodeficiency virus type 1 (HIV-1) mRNAs depends on Rev protein, and intron-containing
HIV-1 transcripts undergo nuclear downregulation as they are further spliced or degraded in
the absence of Rev [39, 40]. This finding may contribute to the short half-lives of unspliced or
partially spliced transcripts ex vivo, even those that have been polyadenylated.
Our data from collagenase-treated PBMCs provide evidence that collagenase treatment of
gut cells is unlikely to promote HIV transcript degradation or selectively alter levels of a partic-
ular transcript. Collectively, our RNA stability and collagenase treatment data suggest that the
differential expression of HIV transcripts in the gut and blood are not explained by either
intrinsic or treatment-mediated changes to HIV RNA stabilities.
Larger block to HIV transcriptional initiation in the rectum
Although the PBMCs and rectal biopsies differ in cell composition, direct comparison between
HIV transcription in these samples was possible using the ratio of HIV RNA to HIV DNA,
which yields a measure of average transcription per provirus. In intact rectal biopsies, the aver-
age levels per provirus of Read-through, total, elongated, Nef, polyadenylated, and multiply-
spliced Tat-Rev transcripts were all lower compared to PBMCs, supporting previous work that
reported lower levels of HIV transcription in the rectum [23, 26]. The sorted CD4+ T cells
showed largely congruent results, where the average levels per provirus of Read-through, total,
and multiply-spliced Tat-Rev transcripts were all lower in the rectal CD4+ T cells than the
blood CD4+ T cells. One notable exception was the average level per provirus of elongated
transcripts, which did not appear to differ between rectal and peripheral CD4+ T cells. More-
over, the TAR/Long LTR ratios suggest a considerable block to elongation in the peripheral
CD4+ T cells (TAR/Long LTR = 7.5) but little block to elongation in the rectal CD4+ T cells
(TAR/Long LTR = 1.31).
This lack of a block to elongation in the rectal CD4+ T cells seems to disagree with the
results from the intact biopsies, where we observed a larger block to elongation. Aside from
differences in the patient cohorts, it is likely that the rectal biopsies contain a different mix of
infected cell types, including non-T cells. Alternatively, it is possible that the tissue processing
(collagenase digestion and shearing) used to dissociate the rectal biopsies into single cells
could change cellular or viral transcription in ways that selectively induce elongation. The con-
trol experiments in PBMCs suggest that collagenase and FACS staining may cause a small
increase in all HIV transcripts, likely reflecting an increase in initiation rather than a specific
effect on elongation, although it is possible that these effects of tissue processing differ in
adherent and nonadherent cells. However, other findings in the sorted gut CD4+ T cells
accord with those in the flash-frozen gut biopsies (which were not subject to such processing)
and suggest that blocks to HIV transcriptional initiation (low TAR RNA per provirus) and
blocks to later stages of HIV transcription (distal transcription, completion, and splicing) may
be important for HIV latency in the gut.
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Our major finding that HIV transcription initiation in the rectal CD4+ T cells is 12-fold
lower than that observed in blood CD4+ T cells (Fig 4B) provides evidence that differing tran-
scriptional blocks operate in different tissues (Fig 5). These findings are particularly striking
given that the gut harbors a much higher proportion of activated CD4+ T cells, and that T cell
activation usually stimulates HIV transcription and reverses latency [10]. It is not clear what
mediates the 12-fold greater block to initiation of HIV transcription in the rectum. Blocks to
HIV transcriptional initiation have been attributed to integration into heterochromatin, epige-
netic modification, transcriptional interference, lack of host transcription initiation factors, or
insufficient activity of the viral transcription factor Tat [41–44]. It seems very unlikely that the
greater block to HIV transcriptional initiation in the gut is driven by higher levels of transcrip-
tional interference from neighboring cellular genes, since levels of Read-through transcripts
per provirus tended to be lower in the gut than blood, the ratio of Read-through to elongated
transcripts tended to be lower in rectal CD4+ T cells than the blood CD4+ T cells, and T cell
activation is supposed to reverse transcriptional interference.
The differences between the blood and gut in the blocks to HIV transcription could be
attributable to either the characteristics of the proviral sequences found in each site or the
Fig 5. Blocks to HIV transcription differ in the gut and blood. Multiple blocks to HIV transcription occur in vivo and these differ in CD4+ T cells from the
rectum and peripheral blood. Selected examples of potential factors are shown.
https://doi.org/10.1371/journal.ppat.1007357.g005
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prevailing host cellular conditions and/or cellular environment. It is possible that proviruses in
the rectum are more likely to be integrated into transcriptionally-silent regions, although most
studies from the blood suggest that HIV is more likely to be integrated in actively-transcribed
genes [45, 46], and the higher levels of T cell activation in the gut might also correlate with
more actively transcribed genes. It is also possible that proviruses in the gut have more or dif-
ferent mutations that could affect transcription, such as those in the LTRs, Tat, or Rev [47–49].
Compartmentalization of HIV could occur in anatomic sites or tissues where viral trafficking
may be impaired or restricted, such as the brain, central nervous system and genital tract [50–
52], but prior studies disagree on whether there is compartmentalization of HIV in the gut
[47–49]. The HIV DNA levels from the rectal biopsies suggest that many proviruses in the rec-
tum have 2 full LTRs (containing U3-U5 and TAR) for every R-U5/pre-Gag and Nef region,
but future studies will be needed to determine whether HIV integration sites or full-length
proviral sequences differ between blood and gut.
Epigenetic modifications, host cell factors, and extracellular milieu at either site may also
dictate the basal transcriptional activity and the consequences for silencing integrated HIV
[30, 45, 46, 53–57]. Previous reports have shown that CD4+ T cell tolerance and anergy can be
mediated by epigenetic modification [58–60]. Given that epigenetic modification (for example,
of the LTR) can also inhibit HIV transcription [56], it is possible that the unique environment
of the gut favors both induction of CD4+ T cell tolerance and HIV latency through epigenetic
modification. The gut and blood also show differences in the phenotypes of HIV-infected and
uninfected cells, which likely differ in the cellular factors that govern HIV transcription. Naïve
and central memory T helper (TCM) cells account for the largest proportion of T lymphocytes
in peripheral blood, while effector memory (TEM) and transitional memory (TTM) constitute
the predominant populations in the gut [10]. Most HIV DNA in the blood is found in central
and transitional memory CD4+ T cells [4], whereas in the gut, most HIV DNA and RNA are
found in effector memory CD4+ T cells [26]. The expansive surface area of the GI mucosa is
under constant exposure to diverse microbial and food antigens, resulting in sustained
immune activation [10]. A higher proportion of gut CD4+ T cells express HIV coreceptors
and markers of T cell activation, which may enhance their susceptibility to infection or deple-
tion during acute infection [10]. The gut is also enriched for tissue resident memory cells and
different subsets of helper T cells, such TFH [61–64], TH17, TH1/TH17 and TH22, which may
serve as reservoirs for latent HIV [10]. In addition, a higher proportion of gut CD4+ T cells
express immune checkpoint blockers such as PD-1 and CTLA-4 [65, 66], which have been
associated with HIV latency [66]. Non-T cells such as macrophages or dendritic cells might
also constitute a larger portion of the infected cells in the gut [26]. These differences in infected
cell types likely contribute to the discordant progression through various transcriptional
blocks observed in these two tissues.
It is not clear which cellular or viral factors might explain the differences between HIV tran-
scriptional blocks in the blood and gut. A multitude of cellular factors reportedly interact with
the HIV LTR to control transcription, and a regulatory feedback mechanism mediated by Tat
and Rev drives HIV transcription through its distinct phases [67, 68]. MS Tat-Rev was more
frequently detected in the blood than the gut, resulting in a lower median level per provirus in
the gut, but MS Tat-Rev may have been harder to detect in the gut because of the lower fre-
quency of CD4+ T cells in the rectal biopsies and the lower yield of sorted CD4+ T cells from
the rectum. If the lower block to elongation in the rectal CD4+ T cells is not the result of induc-
tion of elongation during collagenase digestion, it could reflect higher levels of P-TEFb or
lower levels of NELF in the gut CD4+ T cells, which are more likely to be activated. At the
same time, activation should also increase cellular factors that increase HIV transcriptional ini-
tiation, such as NFAT and NF-κB, but HIV transcriptional initiation was lower in the rectum,
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even in the flash frozen biopsies. It is possible that "activation" markers have different mean-
ings or that T cell activation results in different changes in the gut, where immune cells are
exposed to more microbial products but mechanisms are needed to maintain tolerance to the
normal flora.
In both blood and rectum, we found evidence suggesting blocks to HIV transcriptional
completion and multiple splicing. The block to completion could represent incomplete proces-
sivity of the RNA polymerase II, which could be modulated by protein levels or post-transla-
tional modifications of the enzyme itself, cellular co-factors that affect transcriptional
processivity, or secondary structure in the HIV DNA or RNA. In addition, the block to com-
pletion could reflect viral and cellular factors involved in end processing of HIV transcripts,
including Vpr [69], CDK11 [70, 71], and members of the polyadenylation complex. We have
previously shown that the block to multiple splicing in blood CD4+ T cells is partially reversed
by T cell activation, which could change levels of cellular factors involved in splicing, such as
spliceosome components, SR proteins, MATR3, and PSF [67]. However, a difference between
polyA and Tat-Rev remained even after activation, which could reflect intrinsic sequence-
dependent factors that inhibit HIV splicing (including multiple inefficient splice donor and
acceptor sites, intronic and exonic splice silencers, secondary structure, etc. [67]) as well as
cell-specific differences in activation, proviral mutations affecting Tat-Rev or splice sites [32,
33], and the effect of Rev to export unspliced HIV RNA [67].
The blocks to splicing found in both gut and blood suggest that latency could be governed,
in part, by post-transcriptional mechanisms. This assertion is supported by the observation
that the various latency-reversing agents tested to date fail to completely eradicate infected
cells despite inducing viral transcription, albeit to varying degrees [27, 72]. Post-transcriptional
blocks to HIV expression, such as blocks to nuclear export [73], RNA interference [74–76],
and inefficient translation [77], have been observed in latency models and patient cells. In a
primary cell model of latency, levels of intracellular Gag protein were found to be markedly
low despite high levels of gag RNA [77], and in resting CD4+ T cells from ART-suppressed
individuals, both partially- and fully-spliced HIV transcripts were retained in the nucleus [73],
alluding to a block to nuclear export of HIV RNAs. Polyadenylation is important for nuclear
export [38] as well as translation, so the block to completion could contribute to lack of export
or translation. Because Rev protein facilitates export of unspliced and incompletely-spliced
HIV transcripts from the nucleus [67], the block to multiple splicing could also contribute to
very low levels of Rev and therefore blocks to nuclear export of unspliced and incompletely-
spliced HIV transcripts. Our methods do not allow us to detect other post-transcriptional
blocks, which are possible but would have to be in addition to the blocks described here.
Additional studies are needed to determine what cellular factors govern the different blocks
to HIV transcription and how cellular gene expression differs between infected and uninfected
cells in the blood and gut. Although a limited number of gut biopsies and cells can be obtained
from endoscopic procedures, gut cells from HIV-infected patients could be tested ex vivo for
their responses to T cell activation or drugs known to act on distinct cellular factors, and gut
biopsies could be obtained during clinical trials with interventions designed to disrupt latency.
Other techniques of gut cell isolation, such as those that require either no or alternative colla-
genases [78, 79], could be explored in an effort to minimize tissue processing and potentially
increase dissociated cell recovery. Even if cell recovery is limited, single cell transcriptomic
and/or proteomic studies could also be used to investigate the cellular factors that are associ-
ated with different HIV transcripts in blood and gut cells from patients. Moreover, larger cell
numbers could be obtained from unused tissue left over from surgical resections in either HIV
+ or HIV- patients. Future mechanistic studies could also employ primary cell latency models
derived from lymphoid tissue, such as ‘human lymphocyte aggregate culture’ [80] or ‘lamina
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propria aggregate culture’ [81] systems, which might achieve higher numbers of HIV-infected
cells.
Limitations
In addition to the points addressed above, other limitations of this study should be noted. One
limitation is the relatively small number of ART-suppressed individuals in each of the two
cohorts from whom we had samples from blood and gut. Nonetheless, given the statistically
significant findings from two different cohorts with two distinct types of gut samples, and find-
ings that largely concur with previous work [23, 27], it is likely that there are differences
between blood and gut in the molecular mechanisms that constitutively block HIV trans-
cription. A second limitation is that we did not address the degree to which these blocks are
reversible after T cell activation. However, we have previously demonstrated the reversibility
of the blocks to HIV transcriptional elongation, completion, and splicing in blood CD4+ T
cells [27], so we also expect some reversibility in gut cells, although the magnitude may differ.
Finally, although our transcriptional profiling technique enables us to simultaneously assess
multiple blocks to transcription, these assays are unable to distinguish which of these tran-
scripts originate from replication-competent proviruses. Given the many cellular factors that
can influence HIV transcription independently of viral fitness, the large proportion of the HIV
genome in which mutations could eliminate infectivity without affecting transcription (or,
conversely, could prevent any transcription), and prior evidence suggesting these blocks to
HIV transcription operate in most infected CD4+ T cells from the blood, it seems likely
that the same mechanisms operate in many cells with infectious proviruses. However, this
question is extremely important and should be addressed in future studies, although it is an
exceedingly challenging question to answer using patient cells and will require novel single cell
approaches.
Implications
Findings from this study have important implications. The large disparities between levels of dif-
ferent HIV RNAs in both blood and gut highlight the importance of critically evaluating the
regions targeted when quantifying HIV RNA in different tissue compartments. This fact is
particularly important when designing studies to evaluate the effectiveness of interventions
designed to reverse latency, since putative "latency reversing" agents (LRAs) exert differential
effects on the various transcriptional blocks in blood CD4+ T cells [27], and the same is likely true
in other tissues. For such studies, a multi-target approach, such as the transcriptional profiling
technique applied in this study, might yield greater insight than quantifying unspliced HIV RNA
alone.
The lower levels of HIV transcriptional initiation and of most HIV transcripts per provirus
in the rectum suggest that this site may be enriched for latently-infected cells, cells in a "deeper"
state of latency, or cells in which latency is maintained by different mechanisms. Future studies
are needed to determine whether the same finding holds true in other gut regions or tissues,
and whether these tissues differ from blood in the proportion of cells that contain infectious
proviruses or can be induced by activation to produce infectious viruses. Since infected cells in
the rectum make less HIV RNA (and likely less HIV protein) [23], they may be less likely to
trigger cell-intrinsic defense mechanisms or extrinsic immune responses that are designed to
recognize and kill infected cells. This may facilitate survival of infected cells in the rectum and
might contribute to the higher levels of HIV DNA per million CD4+ T cells in the gut. For the
same reason, HIV-infected cells in the rectum might be less susceptible to killing by immune-
based therapies that require HIV protein or antigen expression, such as broadly-neutralizing
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antibodies to Env, immunomodulators, CAR T cells, and vaccines designed to elicit B or T cell
responses.
Given the stronger block to HIV transcriptional initiation, as well as persistent blocks to
later stages of HIV transcription (completion, splicing) despite higher levels of T cell activa-
tion, infected cells in the rectum may also be less susceptible to agents designed to reverse
latency or may require different LRAs or combinations. Direct evidence for this idea comes
from a recent multi-dose trial of vorinostat in HIV-infected patients, which showed that the
median increase in cell-associated HIV RNA in the rectum was 5-fold less than in the blood
[82]. Future studies should investigate how gut cells differ from blood in the response to differ-
ent LRAs, and whenever feasible, the gut should probably be sampled in clinical trials designed
to evaluate new therapies aimed at HIV cure. Additional studies should investigate how cellu-
lar gene expression differs between CD4+ T cells in the gut and blood, since differentially-
expressed genes might suggest new proteins or pathways involved in suppressing HIV tran-
scription. As an alternative to latency reversal, some recent studies have investigated therapies
designed to create a "deeper" latency and prevent reactivation from latency [83–85]. Infected
gut cells that are activated in vivo but do not transcribe RNA could serve as a model for thera-
pies designed to silence HIV-infected cells. In these ways, an improved understanding of the
mechanisms that govern HIV transcription/latency in the gut and blood could help inform
new therapies aimed at HIV cure, functional cure, or reducing HIV-associated immune activa-
tion and organ damage.
Materials and methods
Ethics statement
The study was approved by the Committee on Human Research (CHR), the Institutional
Review Board for the University of California, San Francisco (approval #11–07551). All study
participants provided written informed consent.
Study participants
The study participants were HIV-infected adults on suppressive ART from two cohorts
(median age = 51; median CD4 count = 611 cells/mm3; median years of suppression = 5).
Matched rectosigmoid biopsies and cryopreserved PBMCs were obtained from study partici-
pants (Table 1) in the Reservoirs and Drug Levels (RADL) study. This study was a prospective,
randomized study designed to measure HIV levels and antiretroviral drug (ARV) levels after
suppression of plasma viremia with ART regimens containing 2 nucleotide inhibitors of
reverse transcriptase and either an integrase inhibitor or a protease inhibitor. Inclusion criteria
included: confirmed HIV-1 infection, ART suppression for�12 months on initial ART regi-
men, plasma HIV-1 RNA <40 copies/mL, and a willingness to undergo rectal biopsy. Matched
blood and gut biopsies were obtained and aliquoted for parallel measurement of ARV levels
and HIV levels. Six rectosigmoid biopsies (flash frozen) and 107 cryopreserved PBMCs were
available from 9 study participants for measurement of HIV levels. Ileal biopsies were available
for three of the 9 study participants.
While these samples offer the advantages of an inclusive mix of cell types and less process-
ing that could affect HIV RNA or drug levels, the PBMCs and gut biopsies also differ in com-
position of infected and uninfected cells. For more direct comparison of CD4+ T cells in the
two tissues, we also sorted CD4+ T cells (defined as CD3+CD8-) from fresh gut biopsies (rec-
tosigmoid +/- ileum) and blood from a different group of 7 ART-suppressed study participants
recruited prospectively and sequentially from the SCOPE cohort (Table 1).
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HIV transcription profile in PBMCs and rectal biopsies
For flash frozen rectosigmoid tissue, 1 mL TRI Reagent with 2.5 μL polyacryl carrier (both
from Molecular Research Center, Cincinnati, OH) was added to the pooled rectal biopsies (six
rectal biopsies per individual), which were homogenized using a Mini Beadbeater (Biospec
Products, Bartlesville, OK). PBMCs from the same participants were thawed quickly and pel-
leted by centrifugation (300g for 5 min at 4˚C). Following centrifugation, cryopreservation
medium was removed and 1 mL TRI Reagent with 2.5 μL polyacryl carrier was added to
homogenize cells. Total cellular RNA and DNA were subsequently extracted per the TRI
Reagent protocol with back extraction for DNA[27].
RNA and DNA concentrations and quality were measured using the Nanodrop 1000 spec-
trophotometer (Thermo Fisher Scientific, Waltham, MA). Up to 1μg of total RNA was used
for a polyadenylation-reverse transcription-ddPCR assay for the TAR region, which is found
in all HIV transcripts. This assay employs an initial polyadenylation step, since efficient reverse
transcription (RT) of short, prematurely-terminated TAR transcripts requires RT from a linker
molecule [31]. Following an RT reaction employing a combination of oligo (dT) and random
hexamers, replicate 5μL aliquots of the cDNA were used in a ddPCR reaction containing TAR-
specific primers and probe. Up to 5μg of RNA was used for a separate 50μL common RT reac-
tion, from which aliquots of cDNA (5μL/well) were used in ddPCR assays for other sequence
regions, including U3-U5 ("Read-through"), R-U5/pre-Gag ("Long LTR"), Nef, U3-R-polyA
("Poly A"), and multiply-spliced Tat-Rev (MS Tat-Rev) regions [27].
Since prior studies suggest that the average level per cell of "housekeeping" transcripts and
the average RNA content per cell differ between cell types or even between corresponding cell
types in different tissues or conditions (such as T cell activation [27, 86, 87]), we did not use
housekeeping transcripts or total cellular RNA to determine the cell equivalents in the RNA
from the PBMCs or rectal biopsies, which contain different mixtures of cell types from differ-
ent tissues. Instead, we determined the total cell equivalents in the DNA extracted from the
same samples as the RNA by measuring the absolute copy numbers of a nonduplicated cellular
gene, Telomere Reverse Transcriptase (TERT), using ddPCR [88]. Using the assumption that
Table 1. Characteristics of HIV-infected study participants.
Participant ID Cohort Gender Age CD4 (cells/mm3) VL Drug Regimen Years of suppression
2125 SCOPE Male 48 828 <40 FTC/TDF, DRV, RTV 10
2298 SCOPE Male 63 254 <40 FTC/TDF, ATV, RTV 9.1
2475 SCOPE Male 54 438 <40 FTC/TDF, ATV, RTV, RAL 5.3
7253 SCOPE Male 62 335 <40 FTC/TDF/EFV 5.5
7259 SCOPE Male 57 523 <40 FTC/TDF/RPV Not available
7260 SCOPE Male 56 388 <40 ABC/DTG/3TC Not available
7244 SCOPE Male 52 432 <40 FTC/TDF, RAL 10
1418 RADL Male 44 717 <40 FTC/TDF, ATV, RTV 4.9
1570 RADL Male 54 592 <40 FTC/TDF, ATV, RTV 2.9
1683 RADL Male 44 837 <40 FTC/TDF, DRV, RTV 3.9
1695 RADL Female 38 688 <40 FTC/TDF, ATV, RTV 5
2470 RADL Male 47 773 <40 FTC/TDF, ATV, RTV 6.4
2474 RADL Male 53 630 <40 FTC/TDF, ATV, RTV 4.6
2531 RADL Male 50 1850 <40 FTC/TDF, RAL 3.4
2536 RADL Male 40 913 <40 FTC/TDF, RAL 2.3
2647 RADL Male 32 587 <40 FTC/TDF, DRV, RTV 3.3
Abbreviations: VL = viral load; 3TC = lamivudine; ATV = atazanavir; DRV = darunavir; DTG = dolutegravir; EFV = efavirenz; FTC = emtricitabine; RAL = raltegravir;
RPV = rilpivirine; RTV = ritonavir; TDF = tenofovir
https://doi.org/10.1371/journal.ppat.1007357.t001
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the extraction efficiency is similar for both DNA and RNA, which we have verified in prior
TRI reagent extractions from PBMCs, we normalized the absolute copy numbers of cDNA in
each well to copies per million cells by using the total cell equivalents in the DNA and the frac-
tion of the total RNA used for each RT and ddPCR [27]. It should be noted that the same
method of normalization was used for each HIV RNA transcript, and therefore would not
explain any difference between levels of various HIV RNAs in the same sample. As an addi-
tional method of normalization, we also normalized levels of each HIV RNA to the total cell
equivalents in the DNA as determined by DNA mass, using the concentration measured by
NanoDrop and the total resuspension volume. The findings were essentially identical.
We also quantified the levels of the U3-U5 ("Read-through"), TAR, Long LTR, and Nef regions
in DNA extracted in parallel with the RNA from the same PBMCs and rectal biopsies (from n = 9
individuals) using the same primers/probes and ddPCR conditions used to measure each HIV
RNA [27]. Since the PolyA assay does not detect HIV DNA, polyadenylated transcripts were nor-
malized to HIV DNA levels of the U3-U5 (Read-through) assay, which contains the U3-R region
of the PolyA assay and shares the same forward primer and probe. Note that we excluded MS
Tat-Rev from this analysis, since this assay also does not detect HIV DNA and spans the two
exons of tat and rev, so there is no DNA equivalent. Cellular DNA was fragmented by passage
through a QIAshredder column [88]. Levels of each HIV DNA sequence region were measured
by ddPCR in replicate aliquots (at least 2) of 500ng DNA/well and expressed as copies per million
cells by levels of TERT (measured in duplicate) in other aliquots from the same DNA.
To further assess the effect of proviral sequences, we calculated the ratio of each HIV RNA
to the corresponding HIV DNA sequence region quantified using the same ddPCR assay and
normalized to 106 cells in the same fashion. This measure expresses the average level of tran-
scription per provirus and is independent of normalization to cell numbers. While this mea-
sure may be best to assess the impact of proviral mutations in each sequence region, it should
be noted that some sequence regions (TAR, "Read-through") are present in 2 copies per intact
HIV DNA (one in each LTR), while the others are present in only one copy. As an alternative
method to express the average transcription per provirus in the PBMCs and biopsies, we also
calculated the ratio of each HIV RNA to HIV DNA as measured using the R-U5/pre-Gag
(Long LTR) assay, which is present in only one copy per intact provirus. This method also
allows comparison of Tat-Rev to the other transcripts. Finally, we calculated the ratios of one
HIV transcript to another, which are independent of normalization to cell numbers and can
be used to measure the presence and degree of different HIV transcriptional blocks [27].
RNA stability
To determine whether sequence-specific differences in RNA stability could contribute to dif-
ferences in levels of the HIV RNAs, we measured the decay of Read-through, TAR, Long LTR,
Nef, PolyA, and MS Tat-Rev transcripts in CD4+ T cells from an ART-suppressed individual
using RNA Pol II inhibitors, Triptolide and Actinomycin D. CD4+ T cells were isolated from
blood from an ART-suppressed individual using the Dynabeads Untouched Human CD4 T
cells kit (Thermo Fisher, Waltham, MA). Replicate aliquots of CD4+ T cells (6x106 cells/well)
were seeded into 6-well tissue culture plates (Corning Inc., Corning, NY) at a concentration of
1x106 cells/ml in complete RPMI with either DMSO (negative control), 100nM Triptolide
(Sigma, St Louis, MO), or 5mg/ml Actinomycin D (Sigma, St Louis, MO). Cells were harvested
at the following time points: DMSO: 0, 1 and 16h; Triptolide: 0, 1, 3, 6 and 16h; Actinomycin
D: 0, 1, 3 and 16h. HIV transcripts (Read-through, TAR, Long LTR, Nef, Poly A, and MS Tat-
Rev) were quantified using RT-ddPCR as described above. Levels of each HIV RNA were
quantified by RT-ddPCR, normalized by alternative measures (cell counts, DNA mass, RNA
Transcriptional blocks underlying HIV latency differ in the gut and blood
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007357 November 15, 2018 18 / 28
mass), and expressed as a fraction of the value at time zero. The half-life for each transcript
was determined using an exponential one-phase decay model.
HIV DNA levels and transcription profile in sorted CD4+ T cells from
blood and rectum
For more direct comparison of CD4+ T cells in the blood and gut, we also analyzed CD4+ T
cells isolated from blood and rectosigmoid (+/- ileum) from a different group of 7 ART-sup-
pressed individuals. Fresh gut biopsies (15–20) were obtained by colonoscopy, placed immedi-
ately in RPMI (supplemented with L-Glutamine, penicillin, streptomycin and 15% fetal calf
serum), washed, and dissociated into total gut cells using collagenase with DNase and mechan-
ical shearing [26]. Blood was obtained immediately before colonoscopy and PBMCs were iso-
lated using Ficoll as previously described [26]. PBMCs and total gut cells were counted,
stained with LIVE/DEAD stain and fluorescently-conjugated antibodies, and sorted for live,
single, CD45+CD3+CD8- cells as previously described [89]. Sort yields from the rectum ran-
ged from 83,474 to 976,738 (median 360,279; S2 Table). Cells were sorted into FACS buffer,
centrifuged to pellet cells, and immediately frozen.
Total cellular RNA and DNA were isolated from the sorted CD3+CD8- cells using TRI
Reagent, as described previously [26]. DNA was resuspended in 20μL (for rectal T cells) to
75μL (for blood T cells with higher cell counts) of QIAGEN buffer EB. 2.2μL were used to mea-
sure the DNA cell equivalents by ddPCR for TERT in duplicate (1μL/well). At least one (and
up to 3) aliquots (5μL/well) were used to measure HIV DNA by ddPCR for the "Long LTR"
region. At least two (and up to 4) aliquots (5μL/well) were used to measure levels of HIV DNA
2-LTR circles using a new ddPCR assay (see below). Levels of HIV DNA (Long LTR) and
2-LTR circles were normalized to copies/106 cells using the absolute levels of TERT (2 copies/
cell) in the DNA and the volumes used for each assay.
Total cellular RNA was resuspended in 20μL of RNase-free water. 5–10μL (no more than
1μg) was used for the polyadenylation-RT-ddPCR assay for TAR, while the remainder was used
for a common RT reaction from which aliquots were used in replicate ddPCR assays for Read-
through, Long LTR, PolyA, and MS Tat-Rev transcripts (S4 Fig) [27]. Since the average level per
cell of "housekeeping" transcripts may differ in CD4+ T cells from blood and gut (which consist
of different mixtures of TH subtypes with differing proportions of activated cells), and we
wanted to reserve as much of the RNA as possible for measurement of the 5 different HIV tran-
scripts, we did not attempt to measure levels of housekeeping transcripts. Instead, HIV RNA
levels were normalized to copies per million cells using the total cell equivalents in the DNA, as
measured using ddPCR for TERT. As an alternative method to normalize the HIV RNA levels
to cell numbers, we also used total cell counts from the sorts; findings were the same.
To express the average level of each transcription per provirus in the sorted CD4+ T cells,
we calculated the ratio of each HIV RNA to HIV DNA (both expressed as copies/106 cells
using normalization to TERT levels) as measured using the R-U5/pre-Gag (Long LTR) assay,
which is present in only one copy per intact provirus. Finally, we calculated the ratios of one
HIV transcript to another, which are independent of normalization to cell numbers and can
be used to measure the presence and degree of different HIV transcriptional blocks [27].
Collagenase treatment of PBMCs
HIV-infected, ART-suppressed individuals were recruited from the SCOPE cohort (individual
2475) and the VA Healthcare System (individual 129). Following a blood draw, PBMCs were iso-
lated using Ficoll as previously described [26]. For individual 2475, a proportion of PBMCs
(40x106 cells) were untreated. The remaining cells were split for two treatment protocols: 1)
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40x106 PBMCs were treated with collagenase as described previously [26] and stained using the
same antibodies employed for sorting CD4+ T cells from blood and gut (CD45, CD3, CD8, and
LIVE/DEAD); 2) 40x106 PBMCs were not treated with collagenase but stained using CD45, CD3,
CD8, and LIVE/DEAD. A similar procedure was followed for individual 129, where 40x106
PBMCs were untreated and 40x106 cells were treated with collagenase, except these cells were not
stained with fluorescently-conjugated antibodies. Following treatments, cells were counted and
aliquoted into 10x106 cells prior to centrifugation to pellet. After removal of supernatant, cells
were directly lysed in TRI reagent and stored at -80˚C until RNA and DNA extraction.
Nucleic acid extraction
Total cellular RNA and DNA were extracted using TRI Reagent (Molecular Research Center, Inc.,
Cincinnati, OH) as per manufacturer’s instructions, with the following modifications: polyacryl
carrier (Molecular Research Center, Inc., Cincinnati, OH) was added to TRI reagent prior to lysis,
RNA was resuspended in RNase free-water, DNA was extracted using back extraction buffer (4M
guanidine thiocyanate, 50mM sodium citrate, 1M Tris), polyacryl carrier was added to the aque-
ous phase containing the DNA, and DNA was resuspended in QIAGEN buffer EB.
Reverse transcription
A common RT reaction was used to generate cDNA for all ddPCR assays except TAR [27].
Each 50μL RT contained cellular RNA, 5μL of 10x Superscript III buffer (Invitrogen, Carlsbad,
CA), 5μL of 50mM MgCl2, 2.5μL of 50ng/μl random hexamers (Invitrogen), 2.5μL of 50μM
dT15, 2.5μL of 10mM dNTPs, 1.25μL of 40U/μL RNaseOUT (Invitrogen), and 2.5μL of 200U/
μL Superscript III RT (Invitrogen). Control RT reactions were performed in parallel with par-
ticipant samples. A ‘6-assay’ synthetic HIV standard was utilized as a positive control [27].
HIV- donor PBMCs and water that was subjected to nucleic extraction by TRI Reagent served
as negative controls for each transcript. The thermocycling conditions were as follows: 25.0˚C
for 10min, 50.0˚C for 50min, followed by an inactivation step at 85.0˚C for 5min.
Polyadenylation-reverse transcription (polyA-RT) for TAR assay
Reverse transcription from a linker molecule (which we achieve using polyA polymerase to
attach a polyA tail) is necessary for efficient reverse transcription of short, prematurely-termi-
nated HIV transcripts limited to the TAR loop [31]. Therefore, a polyadenylation step was
employed prior to reverse transcription and ddPCR for the TAR region [27, 31]. Each polyade-
nylation reaction comprised cellular RNA with 3μL of 10x Superscript III buffer (Invitrogen),
3μL of 50mM MgCl2, 1μL of 10mM ATP (Epicentre), 2μL of 4U/μL poly-A polymerase (Epi-
centre), and 1μL of 40U/μL RNaseOUT (Invitrogen) in a 20μL reaction. The reaction was
incubated at 37μC for 45min prior to addition of RT reaction components, including 1.5μL of
10mM dNTPs (Invitrogen), 1.5μL of 50ng/μL random hexamers (Invitrogen), 1.5μL of 50μM
oligo dT15, and 1μL of 200U/μL Superscript III reverse transcriptase (Invitrogen). Reverse
transcription was performed on the final 30μL reaction at 25.0˚C for 10 min, 50.0˚C for 50
min, followed by an inactivation step at 85.0˚C for 5 min.
Droplet digital PCR (ddPCR)
Droplet digital PCR was employed because it enables absolute quantification, circumvents the
requirement for external HIV standards, and is more forgiving of differences in PCR efficiency
due to sequence mismatches [90]. These assays have been validated previously [27, 31]. cDNA
from each sample was assayed in duplicate wells for Read-through, TAR, Long LTR, PolyA, and
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MS Tat-Rev regions (all samples) and (for rectal biopsies and PBMCs) one replicate for Nef.
Total cellular DNA was used for the following ddPCR assays: 1) TERT (all samples); 2) Long
LTR DNA (all samples); 3) U3-U5 ("Read-through"), TAR, and Nef DNA (PBMCs and rectal
biopsies); and 4) 2-LTR circles (sorted CD4+ T cells). Each reaction consisted of 20μL contain-
ing cDNA (5μL) or DNA, 10μL of ddPCR Supermix for Probes (no dUTP) (Bio-Rad, Hercules,
CA), 900 nM of primers, and 250 nM of probe. Following production of droplet emulsions
using the QX100 Droplet Generator (Bio-Rad), the samples were amplified under the following
thermocycling conditions: 10 minutes at 95˚C, 45 cycles of 30 seconds at 95˚C and 59˚C for 60
seconds, and a final droplet cure step of 10 minutes at 98˚C, using a 7900 Thermal Cycler (Life
Technologies, Carlsbad, CA). Droplets were quantified using the QX100 Droplet Reader (Bio-
Rad Laboratories Inc., Hercules, CA) and analyzed using the QuantaSoft software (version
1.6.6, Bio-Rad Laboratories Inc., Hercules, CA) in the “Absolute” quantification mode. Gates
were set above the negative controls. False positives were rare, generally limited to a single drop-
let, and usually identifiable by abnormally high fluorescence in both channels.
ddPCR for 2-LTR circles
A new ddPCR assay was used to measure levels of 2-LTR circles. Primers were "F Kumar" (5’
GCCTCAATAAAGCTTGCCTTGA 3’; HXB2 522–543) and "R Butler mod 2-LTR" (5’ YCCA
CAGATCAAGGATMTCTTGTC 3’; 51–28). The probe, "P Kumar" (5’ CCAGAGTCACACA
ACAGACGGGCACA 3’; 559–84, was dual labelled with FAM (5’) and Black Hole Quencher
(BHQ; 3’). Each reaction consisted of 20μL containing DNA, 10μL of ddPCR Supermix for
Probes (Bio-Rad, Hercules, CA), 900 nM of primers, and 250 nM of probe. Thermocycling
conditions and analysis were as described above. A 2-LTR junction standard was created to
determine the performance characteristics of the assay. The 2-LTR junction region was ampli-
fied from HIV NL4-3 infected PBMCs using the primers "F Buzon mod 2-LTR" (5’ CTARCT
AGGGAACCCACTGCT 3’; HXB-2 498–518) and "R Buzon 2-LTR" (5’ GTAGTTCTGCCAA
TCAGGGAAG 3’; 92–71), then cloned and sequenced. The copy numbers in the standard
were determined using the calculated molecular weight and the DNA concentration as deter-
mined by NanoDrop. Replicate dilutions of the standard were used in replicate experiments
to determine the detection limit, efficiency, and linearity (S3 Fig). Detection frequencies were
2/6 at 0.9 copy, 3/6 at 1.8 copies, and 6/6 at 3.6 copies or above. No apparent inhibition was
observed with addition of 1 or 2μg of QIAshredded cellular DNA.
Statistics
The Wilcoxon signed rank test was performed to assess differences between levels of different
HIV RNA or DNA sequence regions. Wells with no positive droplets (most common for MS
Tat Rev) were assigned a value of zero for purposes of calculating the median and p values in
Figs 2 and 4, and S1 Fig. The Wilcoxon signed rank tests were also repeated with no value
(blank) for the undetectables, which did not change the major findings. GraphPad Prism (Ver-
sion 5.0) was used for the Wilcoxon tests and exponential one phase decay modeling. As an
additional method to account for undetectable samples, a negative binomial regression analy-
sis was performed in STATA using the cell equivalents used in each ddPCR well and the num-
ber of replicates. The major findings did not change.
Supporting information
S1 Table. Half-lives for HIV transcripts in peripheral CD4+ T cells from an ART-sup-
pressed individual ex vivo.
(PDF)
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S2 Table. Sorted CD4+ T cell numbers for blood, rectum and ileum.
(PDF)
S1 Fig. Copies of HIV DNA per million cells in PBMCs and intact rectal biopsies. HIV
DNA copies per million cells (normalized by reference gene, TERT) from (A) cryopreserved
PBMCs, and (B) intact rectal biopsies are shown (n = 9 matched donors). HIV DNA copies
were measured using the same primers/probes and ddPCR conditions used to measure levels
of each HIV RNA. The median is represented by the black bar. Comparisons between DNA
copies were performed using the Wilcoxon signed-rank test.
(TIF)
S2 Fig. RNA copies per million cells in peripheral CD4+ T cells from an ART-suppressed
individual ex vivo. CD4+ T cells were culture in the absence of RNA Pol II inhibitors and treated
with 0.1% DMSO as vehicle control. Total RNA was extracted from cells harvested at three time-
points (0, 1 and 16 hours). Levels of each HIV transcripts were measured using RT-ddPCR.
(TIF)
S3 Fig. Efficiency for HIV 2-LTR circle standard. To assess the efficiency of our HIV 2-LTR cir-
cle assay, the copy numbers in the 2-LTR standard were determined using the calculated molecular
weight and the DNA concentration as determined by NanoDrop. Replicate dilutions of the stan-
dard were used in replicate experiments to determine the detection limit, efficiency, and linearity.
(TIF)
S4 Fig. HIV cDNA copies per ddPCR well for sorted CD4+ T cells. Replicate values for each
HIV transcript (expressed as absolute copies per ddPCR well) are shown for each individual.
Total cell number analyzed is reported in parentheses for each anatomic site. Note that these
absolute copy numbers per ddPCR well are not corrected for the RNA input into the reverse
transcription reaction or the fraction of the reverse transcription that is used for each ddPCR
well, which differ between TAR and the other assays.
(TIF)
S5 Fig. HIV RNA/DNA ratios for peripheral, rectal, and ileal CD4+ T cells. The levels of
(A) HIV RNA, and (B) average levels per provirus of each transcript (ratio of each HIV RNA
to the Long LTR HIV DNA) were measured in CD4+ T cells isolated from the blood, rectum
and ileum (n = 4 matched individuals).
(TIF)
S6 Fig. Effect of FACS-staining and collagenase on HIV transcription. The levels of HIV
RNAs were assessed in (A) PBMCs with: 1) no further processing; 2) staining for FACS; and 3)
collagenase treatment and FACS staining; and (B) PBMCs with and without collagenase treat-
ment (no FACS staining). Data are reported as copies per million cells normalized by RNA
mass or TERT, and copies per provirus.
(TIF)
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